SBI in $1 billion funding for Sun Pharma’s US deal

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tFWdJlE
via IFTTT

Read More

Indian cancer patients battle shortage of key drugs as platinum costs surge

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues are causing shortages. This forces patients to search extensively for medication. Some drugmakers have reduced production. The situation puts immense pressure on the healthcare system and patients seeking treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32DvEAG
via IFTTT

Read More

India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moderating. Doctors note that physician training and patient education are now crucial for future market expansion. Meanwhile, tirzepatide shows a recovery, maintaining its market position. Competition remains intense with numerous semaglutide brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9B16sJw
via IFTTT

Read More

India willing to open its market to high-quality, innovative pharma products, says commerce minister

India is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug exports. The Indian pharma market is set to double in five years. Global companies are invited to invest in India's vast market and skilled workforce. India is a major supplier of generic medicines and vaccines worldwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yUNzlbi
via IFTTT

Read More

Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supply

Uzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbekistan a key hub for making and supplying medicines in the region. Simplified rules and tax benefits will encourage more investment. This move will boost local healthcare and strengthen trade ties between the two nations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hzZ18xB
via IFTTT

Read More

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iIhEzGt
via IFTTT

Read More

Hospital expansion cycle to keep margins rangebound, but 18 per cent revenue growth trend likely to sustain: Kotak Securities

Indian hospitals are set for strong revenue growth. Brokerage firm Kotak Securities predicts double-digit gains. EBITDA margins are expected to remain stable. This outlook comes despite significant bed expansion. Hospital volumes and diagnostics are showing positive trends. The March quarter performance was robust, with sales and EBITDA growth reported. This indicates a healthy sector outlook for the coming period.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JCirLdg
via IFTTT

Read More